Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News

NEW POST

August 30, 2021 in FIZE Medical Ltd, IMAGIN Medical, Portfolio, Rapha Capital Management

Rapha Capital Leads New $3 Million Convertible Note Financing in Imagin Medical, Inc.

Rapha Capital BioVentures Fund I, LP (RCBVFI) managed by Rapha Capital leads the financing. Kevin Slawin, M.D., a leading urooncologist…
Read More
August 26, 2021 in IMAGIN Medical, Portfolio, Rapha Capital Management

IMAGIN MEDICAL Secures New $3 Million Convertible Note Financing

Rapha Capital BioVentures Fund I, LP (RCBVFI), Leads New Convertible Note Financing Kevin Slawin, MD, a Leading UroOncologist and Manager…
Read More
June 14, 2021 in Demeetra Agbio, Portfolio, Rapha Capital Management

CRISPR Medicine News Interview with Demeetra AgBio CEO, Jack Crawford

Demeetra Agbio, a Rapha portfolio company was recently featured in an article in the leading industry publication, CRISPR News MEDICINE.…
Read More